“Dupilumab Improves Symptom Control, Health-Related Quality of Life and Work Productivity Among Adults With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 6-Year Follow-Up Results From the RELIEVE-AD Study”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s598, https://doi.org/10.25251/2a8shm52.